ASLAN Pharmaceuticals is developing immuno-oncology agents and targeted therapies to treat various cancers by harnessing the body's immune system and specific molecular targets. Their approach aims to improve patient outcomes by providing more effective treatment options with potentially fewer side effects compared to traditional therapies.

BIOMx develops customized bacteriophage therapies to target and eliminate harmful bacteria associated with chronic diseases such as cystic fibrosis and diabetic foot osteomyelitis. By validating proprietary bacterial targets, the company creates tailored phage compositions that enhance treatment efficacy and patient outcomes.

Biotix utilizes an AI-driven platform to identify and develop natural, sustainable ingredients that enhance skin health by supporting the skin microbiome. Their flagship product, Probix, is derived from beneficial microbes and is designed to protect against environmental irritants while promoting collagen production, addressing issues related to skin aging and inflammatory conditions.

Black Diamond Therapeutics develops MasterKey therapies that target genetically defined cancers, specifically non-small cell lung cancer and glioblastoma, by addressing multiple oncogenic mutations with a single treatment approach. This technology aims to overcome resistance mechanisms and reduce toxicities associated with wild-type proteins, enhancing treatment efficacy for a broader patient population.

Bota Bio utilizes synthetic biology and enzyme engineering to produce high-quality bio-preservatives and nutritional supplements from renewable resources, significantly reducing raw material and energy consumption. Their technology addresses the demand for sustainable solutions in the food and personal care industries by replacing petroleum-based processes with efficient biomanufacturing methods.

Eligo offers a CRISPR‑based platform that delivers non‑replicative gene‑editing payloads directly to specific gut bacteria, enabling precise in‑situ modification of microbial genomes with near‑100 % efficiency. The technology can knock out disease‑associated genes, restore beneficial functions, or add therapeutic capabilities while preserving the overall microbiome, supporting both drug development and microbiome research.

Engine Biosciences uses machine learning and high‑throughput biology to map genetic interactions in complex disease networks, identifying therapeutic targets and biomarkers for defined patient groups. It translates these insights into precision medicines and companion diagnostics, focusing on solid tumor indications. The company also offers its platform and assets for partnership to accelerate R&D and clinical development.

The startup develops antibody therapeutics specifically targeting fibro-inflammatory diseases, utilizing a proprietary platform for the design and production of these biologics. This technology provides healthcare professionals with effective treatment options for patients suffering from conditions characterized by excessive inflammation and fibrosis.

Lexe is a self-custodial Bitcoin and Lightning wallet that enables users to receive payments 24/7, even when offline, by utilizing BOLT 12 offers and unified Bitcoin QR codes. The platform simplifies Lightning node management with free hosting and a fixed 0.5% fee per transaction, allowing users to focus on their core activities without the complexities of channel configuration and liquidity balancing.

Provides a software platform that uses LiDAR 3D scanning to automate the measurement of rooms and heating systems, generating DIN-compliant heating load reports in minutes. This streamlines the complex and time-consuming process of manual measurements and calculations, enabling energy consultants and HVAC professionals to optimize residential decarbonization efforts efficiently.

Medra provides a Physical AI platform that captures high-fidelity data from laboratory instruments, both manual and automated, to reduce experimental errors. Its Scientific AI component allows users to program and adapt complex protocols using natural language and multi-modal reasoning. This system enables closed-loop optimization for scientific workflows across genomics, cell biology, and biochemistry applications.

The startup operates a co-working laboratory with biological safety level 2 (BSL-2) facilities, providing essential resources for early-stage biotechnology ventures. This collaborative environment enables biotech startups to access specialized equipment and networking opportunities, facilitating the development and commercialization of their innovations.

Nubank provides a fully digital banking platform that includes a no‑annual‑fee Mastercard credit card, a fee‑free account, and mobile‑first tools for payments, Pix transfers, bill pay, and goal‑based savings containers that earn CDI‑linked returns. It also offers premium products like the Ultravioleta Mastercard Black with cashback and points, and a Nu Empresas card for businesses with real‑time expense tracking and credit limits, all secured with virtual cards, fraud alerts, and 24/7 support.

OpenProtein.AI offers a machine learning platform that enables biologists to enhance protein engineering processes, resulting in faster, more cost-effective, and reliable product development. By providing accessible ML tools, the platform addresses the limitations of traditional methods in protein design and optimization.

PairX develops cancer-selective biologics by identifying prevalent tumor-associated antigens derived from aberrantly spliced proteins, enabling targeted therapies that minimize off-target effects. This approach addresses the limited availability of effective treatment options for large patient populations by focusing on highly selective targets that improve therapeutic efficacy and tolerability.

Senti Biosciences develops proprietary Gene Circuits using synthetic biology to reprogram cells for targeted cancer therapies, enabling precise elimination of cancer cells while sparing healthy tissue. Their lead product candidate, SENTI-202, is designed for the treatment of acute myeloid leukemia, addressing the need for more effective and specific cancer treatments.

Nexus App is a ride-sharing platform that utilizes electric vehicles to provide sustainable transportation while significantly reducing carbon emissions. The service addresses the need for eco-friendly commuting options in urban areas, contributing to lower air pollution and a smaller carbon footprint.

Synlogic develops synthetic biotic medicines that utilize engineered living therapeutics to perform specific metabolic functions, targeting diseases such as phenylketonuria (PKU). By addressing the underlying metabolic deficiencies, these biotherapeutics aim to transform treatment approaches and improve patient outcomes.

Tango Therapeutics is developing targeted cancer therapies using synthetic lethality to specifically target tumor cells based on their genetic profiles. This approach aims to enhance the efficacy of cancer treatments while minimizing harm to healthy tissues, addressing the limitations of traditional therapies.

ZUZU Hospitality provides an all‑in‑one cloud platform for independent hotels in Southeast Asia and India, combining a property management system, AI‑driven dynamic pricing, channel management, and a booking engine. The solution automates yield management, synchronizes inventory across OTAs, and offers real‑time analytics to boost RevPAR while reducing the need for multiple fragmented tools.